It is then counterintuitive that GR agonists are effective in 60–80% of patients with DBA, an inherited form of pure RBC aplasia induced by mutations that impair protein biosynthesis by reducing the synthesis of new ribosomes. The gene discussed is NR3C1; the disease is Diamond-Blackfan anemia.